Review
Oncology
Marco Di Nitto, Fabio Sollazzo, Valentina Biagioli, Gianluca Pucciarelli, Francesco Torino, Rosaria Alvaro, Ercole Vellone
Summary: This review examined self-care behaviors in patients treated with oral anticancer agents. The findings showed that most behaviors focused on medication adherence and there is a need for future interventions to improve self-care in this vulnerable population.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Urology & Nephrology
Celestia S. Higano, Jason Hafron
Summary: This review discusses adherence rates, barriers to compliance, and strategies to overcome challenges in clinical settings. Nonadherence rates of prostate cancer patients with oral therapies range from 25% to 51%, with higher rates in older patients. Medication-related barriers include complex dosing schedules, medication management burden, fasting or dietary requirements, high costs, adverse effects, and drug interactions. Patient-specific barriers include suboptimal education, physical limitations, living alone, high symptom burden, needle phobia, and comorbid mental disorders. Interventions to improve adherence include automated reminders, treatment diaries, and involvement of patients, family members, care partners, and healthcare teams.
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Lisa P. Spees, Stephanie B. Wheeler, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, Tian Zhang, Daniel George, Charles D. Scales, Jessica E. Pritchard, Michael Leapman, Cary P. Gross, Michaela A. Dinan
Summary: The study identified provider and patient-level factors associated with initiation of oral anticancer agents (OAA) in patients with metastatic renal cell carcinoma. It found that provider specialty, gender, and practice location were associated with OAA initiation, while adherence was only influenced by insurance type.
Article
Health Care Sciences & Services
Alessandro Passardi, Flavia Foca, Orazio Caffo, Carlo Alberto Tondini, Alberto Zambelli, Roberto Vespignani, Giulia Bartolini, Francesco Giulio Sullo, Daniele Andreis, Marco Dianti, Claudio Eccher, Enrico Maria Piras, Stefano Forti
Summary: This study tested a platform called ONCO-TreC, which is designed to support home management of oral anticancer treatments and provide secure communication between patients and health care professionals. The results showed that the system has a high ability to measure adherence to treatment and is highly usable and acceptable. However, there is room for improvement in the system's reliability in recording toxicities.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2022)
Review
Chemistry, Multidisciplinary
Seid Reza Falsafi, Yong Wang, Tolulope Joshua Ashaolu, Minaxi Sharma, Shruti Rawal, Kaushika Patel, Gholamreza Askari, Shaghayegh Haghjooy Javanmard, Hadis Rostamabadi
Summary: Cancer, being the second leading cause of death globally, has been addressed using natural anticancer agents due to their pharmacological activities. The oral administration of these agents is limited due to their inherent features. However, the development of nano-driven encapsulation strategies using polymeric vehicles, especially those of natural origin, has shown promise in effectively delivering these agents to the site of action. This review summarizes the challenges of orally delivering natural anticancer agents and the solutions offered by biopolymer matrices, as well as discusses in vitro/in vivo results of oral delivery using various biopolymer vehicles found in literature. It also highlights the challenges and new opportunities in the field.
ADVANCED FUNCTIONAL MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Olivier Mir, Marie Ferrua, Aude Fourcade, Delphine Mathivon, Adeline Duflot-Boukobza, Sarah Dumont, Eric Baudin, Suzette Delaloge, David Malka, Laurence Albiges, Patricia Pautier, Caroline Robert, David Planchard, Stephane de Botton, Florian Scotte, Francois Lemare, May Abbas, Marilene Guillet, Vanessa Puglisi, Mario Di Palma, Etienne Minvielle
Summary: The phase 3 CAPRI clinical trial demonstrates that remote monitoring using a digital nurse navigator-led system improves patient care experience and optimizes healthcare resources for individuals receiving oral anticancer treatment. The intervention leads to increased treatment dose adherence, reduced hospitalization days, and decreased treatment-related toxicities, highlighting the potential benefits of patient-centered care through remote monitoring.
Article
Oncology
Carole Bandiera, Xiomara Skrabal Ross, Evelina Cardoso, Dorothea Wagner, Chantal Csajka, Ian Olver, Pandora Patterson, Vijayaprakash Suppiah, Kate M. Gunn, Marie Schneider
Summary: Not monitoring adherence to oral anticancer therapies can have negative clinical outcomes, including premature death. The implementation of supportive cancer care interventions faces barriers such as hospital sites, cancer diagnoses, and healthcare professionals. This commentary provides insights from OAT adherence trials in Australia and Switzerland to aid in the design and implementation of future interprofessional trials.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Akile Karaaslan-Eser, Sultan Ayaz-Alkaya
Summary: The study demonstrates that a mobile application developed for patients using oral anticancer agents can effectively improve treatment adherence, alleviate symptoms, and support self-management.
EUROPEAN JOURNAL OF ONCOLOGY NURSING
(2021)
Article
Medicine, General & Internal
Deborah Obehi Onwusah, Elizabeth Bolanle Ojewole, Tawanda Manyangadze, Moses John Chimbari
Summary: This study examined the barriers and facilitators of adherence to oral anticancer medications (OAMs) among women receiving breast cancer treatment in Nigeria. The main barriers mentioned were socioeconomic factors (high cost of medication) and therapy-related factors (medication side effects). The key facilitating mechanisms identified included patient-related psychosocial factors such as self-encouragement and self-discipline, as well as practical support from family members.
PATIENT PREFERENCE AND ADHERENCE
(2023)
Article
Health Care Sciences & Services
Orit Cohen Castel, Efrat Dagan, Lital Keinan-Boker, Marcelo Low, Efrat Shadmi
Summary: This study found that better personal continuity between patients and primary care physicians, as well as between patients and oncologists, along with cross-boundary continuity, collectively lead to improved adherence to oral anticancer therapy.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2021)
Article
Oncology
Madilyn Mason, Marcelline R. Harris, Joseph A. Greer, Yun Jiang
Summary: The concept of oral anticancer agent self-management (OAA-SM) and its components, factors, and consequences were clarified in this study. A conceptual model of OAA-SM was proposed. Effective OAA-SM is associated with better patient and healthcare outcomes.
Article
Oncology
Pierre Nizet, Yann Touchefeu, Solange Pecout, Estelle Cauchin, Eva Beaudouin, Severine Mayol, Clementine Fronteau, Jean-Francois Huon
Summary: This study identified factors influencing adherence in cancer patients, including demographic and socioeconomic, disease-related, treatment-related, care system-related, and patient representation and pathways' factors. Most patients highlighted the importance of family support in adherence process and convenience of oral treatment compared to intravenous treatments.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Multidisciplinary Sciences
Irene D. Lin, Matthew B. Shotts, Ahmad Al-Hader, Kellie Jones Weddle, Richard J. Holden, Emily L. Mueller, Monica R. Macik, Mirian Ramirez, Ephrem Abebe
Summary: This scoping review aims to apply a systems framework to examine the system elements targeted by adherence enhancing interventions for oral anticancer medications. By analyzing the systemic barriers targeted by adherence interventions, this review is expected to shed light on the complex and multifaceted nature of factors influencing adherence to oral anticancer agents.
Review
Oncology
Stefania Gori, Alessandra Modena, Jennifer Foglietta, Matteo Verze, Alessandro Inno, Alessandra Casarin, Antonio Russo, Fabrizio Nicolis
Summary: There is an increasing trend towards using oral antitumoral agents in oncological patients, particularly breast cancer patients. However, the benefits of oral drugs will only be realized if patients adhere strictly to the treatment.
Article
Oncology
Justin Gatwood, Ankur Dashputre, Abhijeet Rajpurohit, Katie Gatwood, Emily Mackler, Leah Wallace, Karen Farris, Amna Rizvi-Toner, Joel Farley
Summary: This retrospective cohort study investigated medication use in patients with chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). The study found that the initiation of OAAs did not have a significant impact on medication adherence for chronic diseases.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Oncology
Melanie Powis, Rinku Sutradhar, Aditi Patrikar, Matthew Cheung, Inna Gong, Abi Vijenthira, Lisa K. Hicks, Drew Wilton, Monika K. Krzyzanowska, Simron Singh
Summary: A population-based study in Ontario, Canada found that cancer patients who were recent or nonrecent immigrants and marginalized individuals had lower rates of COVID-19 vaccination. This difference is likely due to the interplay between systemic barriers to access and cultural or social influences.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Simon Cook, Cosmin Munteanu, Efthymios Papadopoulos, Howard Abrams, Jennifer N. Stinson, Eric Pitters, Douglas Stephens, Margaret Lumchick, Urban Emmenegger, Rama Koneru, Janet Papadakos, Armin Shahrokni, Sara Durbano, Ines Menjak, Rajin Mehta, Kristen Haase, Raymond Jang, Monika K. Krzyzanowska, Craig Dale, Jennifer Jones, Manon Lemonde, Shabbir Alibhai, Martine Puts
Summary: Researchers developed a self-reported electronic geriatric assessment tool called CHAMP to improve feasibility and accuracy of assessment and treatment decision making for older adults with cancer. The tool was tested and approved by both older adults and oncology clinicians. The CHAMP tool includes questions and recommendations in various health domains.
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Article
Oncology
Milothy Parthipan, Gregory Feng, Nelly Toledano, Valentina Donison, Henriette Breunis, Abirami Sudharshan, Urban Emmenegger, Antonio Finelli, Padraig Warde, Enrique Soto-Perez-de-Celis, Monika Krzyzanowska, Andrew Matthew, Hance Clarke, Daniel Santa Mina, Shabbir M. H. Alibhai, Martine Puts
Summary: Studying the symptom experiences of older men with metastatic prostate cancer during treatment can help identify unmet supportive care needs and improve patient wellbeing. Previous research has focused on the psychological experience rather than the overall symptom experience. The objective of this study was to understand the lived experience of symptoms and supportive care needs in older men undergoing treatment for metastatic prostate cancer.
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Article
Surgery
Antoine Coupier, Yves Gallien, Olivier Boillot, Thomas Walter, Olivier Guillaud, Melanie Vallin, Elsa Thimonier, Domitille Erard, Jerome Dumortier
Summary: This study describes a cohort of liver transplantation recipients who underwent antineoplastic cytotoxic chemotherapy. The results suggest that immunosuppressive drugs and antineoplastic chemotherapy can be managed satisfactorily in most cases.
CLINICAL TRANSPLANTATION
(2023)
Article
Oncology
Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de la Fouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose
Summary: In this study comparing the starting dose of lenvatinib 18 mg/day with 24 mg/day in RR-DTC patients, no significant difference was found in the health-related quality of life (HRQoL). These findings support the use of the approved lenvatinib starting dose of 24 mg/day in RR-DTC patients.
Article
Oncology
Nicola Fazio, Lorenzo Gervaso, Thorvardur R. Halfdanarson, Mohamad Sonbol, Rachel A. Eiring, Sara Pusceddu, Natalie Prinzi, Benedetta Lombardi Stocchetti, Simona Grozinsky-Glasberg, David J. Gross, Thomas Walter, Patrick Robelin, Catherine Lombard-Bohas, Samuele Frassoni, Vincenzo Bagnardi, Lorenzo Antonuzzo, Clotilde Sparano, Sara Massironi, Fabio Gelsomino, Alberto Bongiovanni, Nicoletta Ranallo, Salvatore Tafuto, Maura Rossi, Mauro Cives, Ibrahim Rasul Kakil, Hytam Hamid, Alessandra Chirco, Michela Squadroni, Anna La Salvia, Jorge Hernando, Johannes Hofland, Anna Koumarianou, Sabrina Boselli, Darina Tamayo, Cristina Mazzon, Manila Rubino, Francesca Spada
Summary: This study investigated patients with neuroendocrine neoplasms (NENs) and confirmed SARS-CoV-2 positivity at the molecular level through a retrospective/prospective worldwide study. The findings indicate a decreasing trend in the incidence of COVID-19 over the years, with older age, non-gastroenteropancreatic primary sites, and diabetes mellitus associated with increased severity and mortality of COVID-19.
ENDOCRINE-RELATED CANCER
(2023)
Review
Endocrinology & Metabolism
Clemence Delhomme, Thomas Walter, Dimitri Arangalage, Gaspard Suc, Olivia Hentic, Agnes Cachier, Soleiman Alkhoder, Laurent Francois, Catherine Lombard-Bohas, Bernard Iung, Philippe Ruszniewski, Louis de Mestier
Summary: Carcinoid heart disease (CHD) is a major complication of carcinoid syndrome (CS) associated with metastatic small intestine neuroendocrine tumors (NETs). The formation of fibrous plaques involving the right side of the heart is mainly caused by vasoactive hormones secreted by NETs, particularly serotonin. Diagnosis of CHD can be delayed as patients are often asymptomatic despite severe heart valve involvement. Treatment of CHD requires a multidisciplinary approach, including antitumor treatment, control of CS, and surgical valve replacement in severe cases.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Pathology
Tanguy Fenouil, Pierre Marie Lavrut, Maud Rabeyrin, Mustapha Adham, Kayvan Mohkam, Jean Yves Mabrut, Thomas Walter, Valerie Hervieu
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a major public health issue with a high incidence/mortality ratio. Only a small percentage of patients with PDAC can have surgery, and even after surgery, there is a high risk of recurrence. Necrosis is found to have a significant impact on overall survival in patients with PDAC.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Surgery
Lea Robin, Alain Sauvanet, Thomas Walter, Haythem Najah, Massimo Falconi, Francois Pattou, Sebastien Gaujoux
Summary: Gastrinoma can be cured by complete resection, but the surgical management for sporadic nonmetastatic gastrinoma is still controversial. This retrospective study analyzed patients who underwent surgery for nonmetastatic sporadic gastrinoma between 2000 and 2020. The study identified predictive factors for overall survival and disease-free survival. The results showed that tumor size and grade were independent predictors of recurrence, and surgical procedures did not significantly affect overall survival and disease-free survival for duodenal gastrinomas.
Review
Health Care Sciences & Services
Saeed Moradian, Roma Maguire, Geoffrey Liu, Monika K. Krzyzanowska, Marcus Butler, Chantal Cheung, Marisa Signorile, Nancy Gregorio, Shiva Ghasemi, Doris Howell
Summary: Advances in cancer treatment have led to longer survival for patients, but they still face physical and psychological symptoms. This systematic review aims to assess the effectiveness of eHealth interventions in supporting cancer patients in managing symptoms and improving their quality of life.
JMIR RESEARCH PROTOCOLS
(2023)
Article
Endocrinology & Metabolism
Lucie Duponchelle, Eric Baudin, Fabien Subtil, Christine Do Cao, Eric Dansin, Marine Perrier, Marie-Pierre Teissier, Magalie Haissaguerre, Xavier Cansouline, Julien Hadoux, Galina Jepiral, Catherine Lombard-Bohas, Olaf Mercier, Francois Tronc, Thomas Walter
Summary: This retrospective study investigated the outcomes of surgery for patients with metastatic primary lung neuroendocrine tumors, and found that surgery was associated with a higher rate of improvement in pulmonary symptoms compared to nonoperative treatment. Furthermore, the study found no postoperative mortality and a low rate of major complications in the operative group. These results suggest that surgery may be a safe option for selected patients in order to improve their quality of life.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Gregory Kaltsas, Thomas Walter, Ulrich Knigge, Christos Toumpanakis, Ana P. Santos, Nehara Begum, Ulrich F. Pape, Marco Volante, Andrea Frilling, Anne Couvelard
Summary: The aim of this guidance paper is to provide up-to-date practical guidance for the diagnosis and management of well differentiated appendiceal neuroendocrine tumors (NET). The paper addresses controversial issues and areas of uncertainty, offering recommendations based on the best available evidence and the authors' experiences.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Gastroenterology & Hepatology
Marine Perrier, Charbel Mouawad, Delphine Gueguen, Benoit Thom, Maryse Lapeyre-Mestre, Thomas Walter
Summary: This study used the French national health care data system to describe healthcare resource utilization and costs among patients with neuroendocrine tumors and carcinoid syndrome (CS). The first year following diagnosis and the year preceding death were found to be the periods with the highest costs for CS care in France. Successful disease management may contribute to lower costs in the intermediate period.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2023)
Review
Oncology
Marine Perrier, Jean-Yves Scoazec, Thomas Walter
Summary: According to the characteristics of neuroendocrine tumors (NET), there are 3 to 7 different treatment options, corresponding to 6 to 5,040 theoretical different sequences. Despite heterogeneity in NET characteristics, this review discusses main sequences and proposes a case-by-case basis for treating metastatic NET (mNET). Each treatment should be discussed in multi-disciplinary meetings, and clinical trials should be favored. The first-line treatment should be chosen based on treatment aim, taking into account efficacy, safety, and patient preferences. Real-world data using long follow-up durations are necessary to improve knowledge regarding effectiveness and risk of cumulative toxicities for different sequences.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Thomas Walter, Astrid Lievre, Romain Coriat, David Malka, Farid Elhajbi, Frederic Di Fiore, Olivia Hentic, Denis Smith, Vincent Hautefeuille, Guillaume Roquin, Marine Perrier, Laetitia Dahan, Victoire Granger, Iradj Sobhani, Laurent Mineur, Patricia Niccoli, Eric Assenat, Jean-Yves Scoazec, Karine Le Malicot, Come Lepage, Catherine Lombard-Bohas
Summary: This study evaluates the efficacy of FOLFIRI plus bevacizumab and FOLFIRI alone as second-line treatment for gastroenteropancreatic neuroendocrine carcinoma. The addition of bevacizumab did not seem to improve overall survival compared to FOLFIRI alone, suggesting that FOLFIRI could be considered as the standard second-line treatment for this type of cancer.